Breast Cancer

The FDA has granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy), the first antibody-drug conjugate that targets the Trop-2 antigen. Trodelvy is indicated for treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC). Chemotherapy has been the standard treatment for TNBC, and patients who take Trodelvy must have received at least 2 previous therapies for the cancer. Further clinical...

Although the overall rate of people dying from cancer in the United States has dropped 27% in the past 25 years, some disadvantaged populations didn’t see the same decline. “We’re making progress against cancer in the United States, but some groups aren’t benefitting as much as others,” said Kassandra Alcaraz, PhD, MPH. “Health is affected...